A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients

Trial Profile

A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs RG 7667 (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 13 Nov 2017 Results assessing the safety and pharmacological activity of multiple doses of RG7667 in preventing CMV infection in kidney transplant recipients, were published in the Antimicrobial Agents and Chemotherapy.
    • 12 Nov 2016 Primary endpoint (Percentage of Participants With CMV Viral Load Greater than or Equal to 150 Copies per Milliliter (Copies/mL) During the First 12 Weeks After Transplantation) has not been met,according to the results published in the Antimicrobial Agents and Chemotherapy.
    • 12 Nov 2016 Results published in the Antimicrobial Agents and Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top